While GLP1 agonists have gained popularity in the pharmaceutical treatment of T2DM and obesity, previous work has demonstrated that the microbiota is involved in GLP1 secretion42,43 and treatment efficacy44. This evidence concerns the gene GCG and type 2 diabetes mellitus.